Normal view MARC view ISBD view

Tissue-Specific Estrogen Action [electronic resource] :Novel Mechanisms, Novel Ligands, Novel Therapies / edited by K. S. Korach, T. Wintermantel.

by Korach, K. S [editor.]; Wintermantel, T [editor.]; SpringerLink (Online service).
Material type: materialTypeLabelBookSeries: Ernst Schering Foundation Symposium Proceedings: 2006/1Publisher: Berlin, Heidelberg : Springer Berlin Heidelberg : 2007.Description: XV, 181 p. 42 illus. online resource.ISBN: 9783540495482.Subject(s): Medicine | Toxicology | Gynecology | Endocrinology | Biochemistry | Medicine & Public Health | Endocrinology | Gynecology | Medical Biochemistry | Molecular Medicine | Pharmacology/ToxicologyDDC classification: 616.4 Online resources: Click here to access online
Contents:
Interfering with the Dynamics of Estrogen Receptor-Regulated Transcription -- Actions of Estrogen and Estrogen Receptors in Nonclassical Target Tissues -- Genetic Dissection of Estrogen Receptor Signaling In Vivo -- Of Mice and Men: The Many Guises of Estrogens -- Estradiol Action in Atherosclerosis and Reendothelialization -- Functional Effects and Molecular Mechanisms of Subtype-Selective ER? and ER? Agonists in the Cardiovascular System -- Pathogenesis and Therapy of Rheumatoid Arthritis -- The Role of ER? and ER? in theProstate: Insights from Genetic Models and Isoform-Selective Ligands -- Preclinical Characterization of Selective Estrogen Receptor ? Agonists: New Insights into Their Therapeutic Potential -- Exploiting Nongenomic Estrogen Receptor-Mediated Signaling for the Development of Pathway-Selective Estrogen Receptor Ligands.
In: Springer eBooksSummary: The multiple actions of estrogens on different cell types have not only intrigued endocrinology researchers but also inspired the development of selective estrogen receptor modulators, or SERMs, that modulate estrogen signaling in a cell type-specific manner. Current molecular understanding of estrogen action has greatly profited from advances in molecular cell biology to dissect the mechanisms of estrogen-regulated gene expression in target cells, from in vivo analyses using genetic models deficient in estrogen signaling and from synthetic estrogen receptor ligands with isoform- or pathway-selective activity. These advances, and their implications for clinical use, were discussed by leading researchers from industry and academia during an international symposium held in Berlin, 1-3 March 2006.
Tags from this library: No tags from this library for this title. Add tag(s)
Log in to add tags.
    average rating: 0.0 (0 votes)
Item type Current location Call number Status Date due Barcode
MAIN LIBRARY
RC648-665.2 (Browse shelf) Available

Interfering with the Dynamics of Estrogen Receptor-Regulated Transcription -- Actions of Estrogen and Estrogen Receptors in Nonclassical Target Tissues -- Genetic Dissection of Estrogen Receptor Signaling In Vivo -- Of Mice and Men: The Many Guises of Estrogens -- Estradiol Action in Atherosclerosis and Reendothelialization -- Functional Effects and Molecular Mechanisms of Subtype-Selective ER? and ER? Agonists in the Cardiovascular System -- Pathogenesis and Therapy of Rheumatoid Arthritis -- The Role of ER? and ER? in theProstate: Insights from Genetic Models and Isoform-Selective Ligands -- Preclinical Characterization of Selective Estrogen Receptor ? Agonists: New Insights into Their Therapeutic Potential -- Exploiting Nongenomic Estrogen Receptor-Mediated Signaling for the Development of Pathway-Selective Estrogen Receptor Ligands.

The multiple actions of estrogens on different cell types have not only intrigued endocrinology researchers but also inspired the development of selective estrogen receptor modulators, or SERMs, that modulate estrogen signaling in a cell type-specific manner. Current molecular understanding of estrogen action has greatly profited from advances in molecular cell biology to dissect the mechanisms of estrogen-regulated gene expression in target cells, from in vivo analyses using genetic models deficient in estrogen signaling and from synthetic estrogen receptor ligands with isoform- or pathway-selective activity. These advances, and their implications for clinical use, were discussed by leading researchers from industry and academia during an international symposium held in Berlin, 1-3 March 2006.

There are no comments for this item.

Log in to your account to post a comment.
@ Jomo Kenyatta University Of Agriculture and Technology Library

Powered by Koha